You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

392 Results
Document
Jun 2024
Document
Jun 2024
Guidelines and Advice
Status: Current
Version: PET 2023-2
Jun 2024
Document
Jul 2024
Document
Jul 2024
Document
Jul 2024
Document
Jul 2024
Drug
Other Name(s): Epkinly™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
Enhertu trastuzumab deruxtecan (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
 
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer
New Drug Funding Program
    Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enfortumab vedotin,
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025

Pages